Skip to content

Study · Systematic review · 2024

10 results

Effectiveness of pharmacological interventions for managing obesity in children and adolescents: A systematic review and meta-analysis framed using minimal important difference estimates based on GRADE guidance to inform a clinical practice guideline.

Wahi G, St-Pierre J, Johnston BC, Fitzpatrick-Lewis D, Usman A, Sherifali D, Merdad R, Esmaeilinezhad Z, Birken CS, Hamilton J, Henderson M, Moore SA, Ball GDC, Morrison KM

Pediatric obesity6 Sept 2024Cited by 10 (Europe PMC)

PMID39238400 (opens in a new tab)DOI10.1111/ijpo.13169 (opens in a new tab)PepBankPUB-39238400
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In children and adolescents, liraglutide (2 RCTs) gave a small reduction in HOMA-IR.

    In plain wordsIn children and adolescents, liraglutide gave a small drop in insulin resistance (HOMA-IR) in two trials.

    Peptide
    Liraglutide
    Outcome
    DecreaseHOMA-IR
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide (2 RCTs) resulted in a small reduction in HOMA-IR and BMIz, but little to no benefit on other outcomes.
    1 context sentence
    Summary · context
    A systematic review and meta-analysis were conducted of randomized controlled trials (RCTs) with <18-year-olds of pharmacotherapeutic agents published up to November 2022.
  2. 02HumanSystematic reviewEfficacy outcome

    In children and adolescents, liraglutide (2 RCTs) gave a small reduction in BMI z-score.

    In plain wordsIn children and adolescents, liraglutide gave a small drop in BMI z-score in two trials.

    Peptide
    Liraglutide
    Outcome
    DecreaseBMI z-score
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide (2 RCTs) resulted in a small reduction in HOMA-IR and BMIz, but little to no benefit on other outcomes.
    1 context sentence
    Summary · context
    A systematic review and meta-analysis were conducted of randomized controlled trials (RCTs) with <18-year-olds of pharmacotherapeutic agents published up to November 2022.
  3. 03HumanSystematic reviewEfficacy outcome

    In children and adolescents, liraglutide (2 RCTs) had little to no benefit on the other outcomes measured.

    In plain wordsIn children and adolescents, liraglutide showed little to no benefit on the other outcomes measured in two trials.

    Peptide
    Liraglutide
    Outcome
    No significant changeOther outcomes
    Study

    n: not reported in source

    Outcome group
    Overall treatment effect · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide (2 RCTs) resulted in a small reduction in HOMA-IR and BMIz, but little to no benefit on other outcomes.
    1 context sentence
    Summary · context
    A systematic review and meta-analysis were conducted of randomized controlled trials (RCTs) with <18-year-olds of pharmacotherapeutic agents published up to November 2022.
  4. 04HumanSystematic reviewEfficacy outcome

    In children and adolescents, semaglutide (1 RCT) gave a small benefit on health-related quality of life.

    In plain wordsIn children and adolescents, semaglutide gave a small benefit on quality of life in one trial.

    Peptide
    Semaglutide
    Outcome
    IncreaseHealth-related quality of life
    Study

    n: not reported in source

    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semaglutide (1 RCT) had a small benefit on HRQoL, a small reduction on SBP, a moderate reduction on total cholesterol and LDL-cholesterol, a large reduction on triglyceride, and a very large decline in BMIz accompanied by a small increase in mild to moderate gastrointestinal AEs.
    1 context sentence
    Summary · context
    A systematic review and meta-analysis were conducted of randomized controlled trials (RCTs) with <18-year-olds of pharmacotherapeutic agents published up to November 2022.
  5. 05HumanSystematic reviewEfficacy outcome

    In children and adolescents, semaglutide (1 RCT) gave a small reduction in systolic blood pressure.

    In plain wordsIn children and adolescents, semaglutide gave a small drop in systolic blood pressure in one trial.

    Peptide
    Semaglutide
    Outcome
    DecreaseSystolic blood pressure
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semaglutide (1 RCT) had a small benefit on HRQoL, a small reduction on SBP, a moderate reduction on total cholesterol and LDL-cholesterol, a large reduction on triglyceride, and a very large decline in BMIz accompanied by a small increase in mild to moderate gastrointestinal AEs.
    1 context sentence
    Summary · context
    A systematic review and meta-analysis were conducted of randomized controlled trials (RCTs) with <18-year-olds of pharmacotherapeutic agents published up to November 2022.
  6. 06HumanSystematic reviewEfficacy outcome

    In children and adolescents, semaglutide (1 RCT) gave a moderate reduction in total cholesterol.

    In plain wordsIn children and adolescents, semaglutide gave a moderate drop in total cholesterol in one trial.

    Peptide
    Semaglutide
    Outcome
    DecreaseTotal cholesterol
    Study

    n: not reported in source

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semaglutide (1 RCT) had a small benefit on HRQoL, a small reduction on SBP, a moderate reduction on total cholesterol and LDL-cholesterol, a large reduction on triglyceride, and a very large decline in BMIz accompanied by a small increase in mild to moderate gastrointestinal AEs.
    1 context sentence
    Summary · context
    A systematic review and meta-analysis were conducted of randomized controlled trials (RCTs) with <18-year-olds of pharmacotherapeutic agents published up to November 2022.
  7. 07HumanSystematic reviewEfficacy outcome

    In children and adolescents, semaglutide (1 RCT) gave a moderate reduction in LDL-cholesterol.

    In plain wordsIn children and adolescents, semaglutide gave a moderate drop in LDL-cholesterol in one trial.

    Peptide
    Semaglutide
    Outcome
    DecreaseLDL-cholesterol
    Study

    n: not reported in source

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semaglutide (1 RCT) had a small benefit on HRQoL, a small reduction on SBP, a moderate reduction on total cholesterol and LDL-cholesterol, a large reduction on triglyceride, and a very large decline in BMIz accompanied by a small increase in mild to moderate gastrointestinal AEs.
    1 context sentence
    Summary · context
    A systematic review and meta-analysis were conducted of randomized controlled trials (RCTs) with <18-year-olds of pharmacotherapeutic agents published up to November 2022.
  8. 08HumanSystematic reviewEfficacy outcome

    In children and adolescents, semaglutide (1 RCT) gave a large reduction in triglycerides.

    In plain wordsIn children and adolescents, semaglutide gave a large drop in triglycerides in one trial.

    Peptide
    Semaglutide
    Outcome
    DecreaseTriglycerides
    Study

    n: not reported in source

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semaglutide (1 RCT) had a small benefit on HRQoL, a small reduction on SBP, a moderate reduction on total cholesterol and LDL-cholesterol, a large reduction on triglyceride, and a very large decline in BMIz accompanied by a small increase in mild to moderate gastrointestinal AEs.
    1 context sentence
    Summary · context
    A systematic review and meta-analysis were conducted of randomized controlled trials (RCTs) with <18-year-olds of pharmacotherapeutic agents published up to November 2022.
  9. 09HumanSystematic reviewEfficacy outcome

    In children and adolescents, semaglutide (1 RCT) gave a very large decline in BMI z-score.

    In plain wordsIn children and adolescents, semaglutide gave a very large drop in BMI z-score in one trial.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI z-score
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semaglutide (1 RCT) had a small benefit on HRQoL, a small reduction on SBP, a moderate reduction on total cholesterol and LDL-cholesterol, a large reduction on triglyceride, and a very large decline in BMIz accompanied by a small increase in mild to moderate gastrointestinal AEs.
    1 context sentence
    Summary · context
    A systematic review and meta-analysis were conducted of randomized controlled trials (RCTs) with <18-year-olds of pharmacotherapeutic agents published up to November 2022.
  10. 10HumanSystematic reviewSafety outcome

    In children and adolescents, semaglutide (1 RCT) was accompanied by a small increase in mild to moderate gastrointestinal adverse events.

    In plain wordsIn children and adolescents, semaglutide came with a small increase in mild to moderate stomach and bowel side effects in one trial.

    Peptide
    Semaglutide
    Outcome
    IncreaseMild to moderate gastrointestinal adverse events
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semaglutide (1 RCT) had a small benefit on HRQoL, a small reduction on SBP, a moderate reduction on total cholesterol and LDL-cholesterol, a large reduction on triglyceride, and a very large decline in BMIz accompanied by a small increase in mild to moderate gastrointestinal AEs.
    1 context sentence
    Summary · context
    A systematic review and meta-analysis were conducted of randomized controlled trials (RCTs) with <18-year-olds of pharmacotherapeutic agents published up to November 2022.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.